Cholangiocarcinoma, also known as bile duct cancer, is one of those rare diseases that previously gained little attention from the biopharma community. It has a small population and is challenging to treat. About 8,000 people in the U.S. are diagnosed each year, and most learn they have the disease at the late stages when the prognosis is poor. Read More
PERTH, Australia – Following its IPO on Australia's Securities Exchange last year, radiopharma company Telix Pharmaceuticals Ltd. has been building global partnerships to prepare for a commercial build-up of its theranostic radiopharmaceuticals. To add to its arsenal, Telix has exercised an option to acquire Atlab Pharma SAS for $10 million to de-risk its prostate cancer monoclonal antibody (MAb), TLX-591. Read More
Many people wonder whether amyloid beta-targeting antibodies will ever prove to be a success in fighting Alzheimer's disease. Todd Golde is pretty sure that day will come. Read More
Epic Sciences has added a pair of private equity investors and another strategic investor with its series E round of $52 million. That puts it in an optimal spot for a potential IPO and for strategic dealmaking. The round was led by health care private equity firm Blue Ox Healthcare Partners, with participation by another health care PE group, Deerfield Management, and cancer radiotherapy company Varian Medical Systems Inc. Read More
In an update provided by the FDA, the agency said its latest testing shows an additional unexpected impurity in three lots of recalled valsartan drug products from Torrent Pharmaceuticals Ltd., of Gujarat, India. The second impurity, N-nitrosodiethylamine (NDEA), is a known animal and suspected human carcinogen. Read More
Researchers from the University of Utah have shown that CRISPR/Cas9 cleavage ability was affected by chromatin structure; more surprisingly, perhaps, they have also shown that the cleavage ability of zinc finger nucleases were only minimally affected. Read More
Seeking to unite FDA efforts to combat antimicrobial resistance (AMR), Commissioner Scott Gottlieb outlined a new strategy to use stewardship and science to slow the threat's pace and reduce its impact. The plan seeks to better facilitate and pep up new antimicrobial product development as the field wrestles with new ideas about how to overcome the market's discouraging economics. Read More
Supernus Pharmaceuticals Inc. plans to acquire Biscayne Neurotherapeutics Inc. and its phase I candidate, BIS-001, in a bid to expand its neurology pipeline. Read More
Cel-Sci Corp., of Vienna, Va., received about $5.4 million through exercise of warrants to purchase shares of the company's common stock during August through Sept. 13. Cel-Sci is in phase III testing with its Multikine candidate in head and neck cancer. Read More
Sun Pharmaceutical Industries Ltd., of Mumbai, India, and subsidiary Sun Pharma Advanced Research Co. Ltd. (SPARC), of Princeton, N.J., received FDA approval for Xelpros (latanoprost ophthalmic emulsion), triggering an undisclosed milestone payment to SPARC under the firms' 2015 deal. SPARC also is eligible for milestones and royalties on commercialization of Xelpros in the U.S. Read More
